Carcereny E, Felip E, Reck M, et al. Updated Efficacy Results From the BIRCH Study: First-Line Atezolizumab Therapy in PD-L1–Selected Patients With Advanced NSCLC. 18th World Conference on Lung Cancer (WCLC) 2017, abstract OA 17.02.
Immuuntherapie ook in de echte wereld succesvol bij gevorderd merkelcelcarcinoom
dec 2020 | Dermato-oncologie, Immuuntherapie